Barclays Raises TEVA Price Target to $47

Barclays maintains a positive outlook on Teva, adjusting its price target based on recent performance, a 13.31% upside from the current price.

By EarningsIQ Research Desk · Published Oct 16, 2026, 11:15 AM EDT · Updated Oct 16, 2026, 11:15 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Barclays raised its price target on Teva Pharmaceutical Industries Limited ($TEVA) to $47 from $42 on October 15, 2026, and rates the stock "Overweight".

Since the rating, $TEVA is up 0.9% to date (from the $41.11 close on Oct 15, 2026).

TEVA Teva Pharmaceutical Industries Limited

$41.50 +34.09% year to date

Daily close · Oct 16, 2026

Key Points

On October 15, Barclays reiterated its Overweight rating on Teva Pharmaceutical Industries, raising its price target from $42.00 to $47.00.
Barclays's $47 price target implies 13.31% upside from Teva Pharmaceutical Industries Limited's ($TEVA) current $41.48 share price.
Teva shares recently traded at $41.03, which is below the new analyst target but above key moving averages.
The company is set to report earnings on November 3, 2026, following a year-over-year revenue decline of 0.8%.

Get $TEVA trade alerts by text

We text you when insiders, Congress or big funds trade $TEVA. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Teva Pharmaceutical Industries Limited alert may contain errors. Disclosures

On October 15, 2026, Barclays reiterated its Overweight rating on Teva Pharmaceutical Industries Limited (NYSE: TEVA) and raised its price target from $42.00 to $47.00. This adjustment reflects the firm's continued confidence in Teva's potential despite a challenging environment.

Analyst rating track record

Barclays vs. the S&P 500

YTD return -0.32% hypothetical

All-time return -0.32% S&P 500 +4.20%

vs. S&P 500 -4.52% behind the index

Hypothetical returns from Barclays's disclosed trades, not real profit or advice. How we model this.

Other Institutional Activity in Teva

Several other institutional investors have made adjustments to their positions in Teva. Blackrock Inc. reduced its stake by 1,244,144 shares, ending with 63,894,301 shares valued at about $2.65 billion. Harel Insurance Investments & Financial Services Ltd. increased its holdings by 2,182,905 shares, bringing its total to 48,138,805 shares worth approximately $2.00 billion. Phoenix Financial Ltd. added 154,006 shares, resulting in a total of 42,933,367 shares valued at around $1.78 billion. WCM Investment Management, LLC grew its stake by 493,938 shares, totaling 41,315,232 shares worth about $1.71 billion. Clal Insurance Enterprises Holdings Ltd. increased its position by 2,149,204 shares, ending with 40,596,506 shares valued at about $1.68 billion.

Teva Pharmaceutical Industries Limited Stock Up 1.9%

Teva shares recently traded at $41.03 as of October 16, 2026. This price is above the 50-day moving average by 7.6% and the 200-day moving average by 20.3%. However, it remains about 2.4% below the 52-week high of $42.02. The stock is also below the mean analyst target of $47.58, suggesting room for growth if the company can meet expectations.

12-month forecast

$TEVA price target

Teva Pharmaceutical Industries Limited daily closes and this analyst's $47 target. Not advice.

Recent Earnings

Teva reported trailing twelve-month revenue of approximately $17.32 billion and an earnings per share (EPS) of $0.59. The company has a net margin of 4.1% and a return on equity (ROE) of 9.7%. The next earnings report is scheduled for November 3, 2026.

Insider Buying and Selling at Teva Pharmaceutical Industries Limited

Insider activity at Teva includes several sales. Eric A. Hughes, an officer, sold 25,578 shares on August 3, 2026, valued at about $892,051, at an average price of $34.88. Amir Weiss, another officer, sold 9,445 shares on August 21, 2026, totaling approximately $355,301. Brian Savage, also an officer, sold 7,342 shares on September 18, 2026, valued at around $285,215. Director Roberto A. Mignone sold 367,600 shares on the same day for about $14.36 million at an average price of $39.06.

Analysts Set New Price Targets

On October 15, 2026, Barclays maintained its Overweight rating on Teva with a new price target of $47.00. Earlier, on October 12, JP Morgan also maintained its Overweight rating, raising its target from $40.00 to $50.00. Other firms like Leerink Partners and Oppenheimer initiated coverage with Outperform ratings and targets of $45.00 and $50.00, respectively.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a global leader in developing and distributing generic and specialty medicines. Headquartered in Tel Aviv-Yafo, Israel, the company serves markets in the U.S., Europe, and Israel. Teva's commitment to affordable healthcare is reflected in its extensive portfolio of generic drugs and biopharmaceutical products.

Bottom Line

Investors should watch for Teva's upcoming earnings report on November 3, 2026, which will provide more insight into its financial health. Barclays' reaffirmed rating and adjusted price target suggest continued interest in the stock, despite its current position relative to analyst expectations.